1 Min Read
NEW YORK, May 22 (Reuters) - Oncolytics Biotech Inc : * Oncolytics Biotech U.S.-listed shares jump 10.3 percent to $3 in premarket after phase 2 metastatic melanoma trial results
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.